Leaflet SINDOVIN 1mg lyophilisate for solution for injection / infusion IV

Indicated for: cancer

Route of administration: infusion / intravenous

Substance: vincristine (antineoplastic agent)

ATC: L01CA02 (Antineoplastic and immunomodulating agents | Plant alkaloids and other natural products | Vinca alkaloids and analogues)

Precautions:
Fertility warning
Fertility warning

This medicine may affect fertility.

Dose adjustment in hepatic impairment
Dose adjustment in hepatic impairment

Dose adjustment may be needed in liver disease.

Cytotoxic / special handling
Cytotoxic / special handling

Handle with special care.

Contraception required
Contraception required

Effective contraception is required during treatment.

Contraindicated during breastfeeding
Contraindicated during breastfeeding

Do not use this medicine while breastfeeding.

Contraindicated during pregnancy
Contraindicated during pregnancy

Do not use this medicine during pregnancy.

Hepatotoxicity
Hepatotoxicity

This medicine may affect the liver.

Major drug interactions
Major drug interactions

This medicine may have important interactions with other medicines.

Myelosuppression / agranulocytosis
Myelosuppression / agranulocytosis

This medicine may lower blood cell counts.

Additional monitoring
Additional monitoring

This medicine is subject to additional monitoring.

Requires periodic laboratory tests
Requires periodic laboratory tests

Periodic laboratory tests may be required during treatment.

Neuropathy / neurotoxicity
Neuropathy / neurotoxicity

This medicine may affect the nerves or nervous system.

Severe skin reactions
Severe skin reactions

Stop taking the medicine and seek urgent medical help if a severe rash occurs.

Vincristine is a chemotherapy medication used for the treatment of various types of cancer, including acute lymphoblastic leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, and Ewing's sarcoma. It belongs to the vinca alkaloid class and works by inhibiting microtubule formation, leading to the arrest of cell division and tumor cell death.

Vincristine is administered intravenously, usually once a week, and the dosage is adjusted based on body weight and patient response. Treatment is conducted under the supervision of an oncologist, and patients are monitored for signs of toxicity.

Common side effects include peripheral neuropathy, constipation, hair loss, nausea, and fatigue. In rare cases, severe adverse reactions such as liver function impairment or bone marrow depression may occur.

Vincristine is an essential component of many chemotherapy regimens, helping to reduce tumor size and improve survival rates in cancer patients.

General data about SINDOVIN 1mg

  • Substance: vincristine
  • Date of latest medicines list: 01-07-2013
  • Product code: W07412001
  • Concentration: 1mg
  • Pharmaceutical form: lyophilisate for solution for injection / infusion IV
  • Quantity: 1
  • Product type: Generic medicine
  • Prescription status: S - Medicines dispensed with a restricted medical prescription, reserved for use in certain specialized fields.

Concentrations available for vincristine

  • 1mg
  • 1mg/ml